Rein Therapeutics Inc.
NASDAQRNTX short interest explodes 144% in one week to 4.5% of float, driven by biotech volatility and clinical uncertainty.
Short interest % of float, cost to borrow, utilization, and put/call ratio for RNTX are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 7 May 2026
No long-form analysis yet for RNTX. Pulse alerts and the live data picture are available on ORTEX.
Open RNTX on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RNTX — free to start on ORTEX.
Sign up for free →Open RNTX on ORTEX